News & Events

• April 13, 2015
  

  Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers

  April 13, 2015 Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers FDA and EMA Letters of Support Suggest Valuable Research Potential TUCSON, Ariz., April 8, 2015 – The Critical Path Institute (C-Path) announced today that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued Biomarker...
• April 13, 2015
  

  Intro to ePRO – Part II

  This webinar provides an overview of current ePRO data collection modes, the mode selection process, key considerations for selecting the most appropriate mode for a study and considerations for migrating an existing PRO instrument to an electronic mode. Presenters: Cindy Howry, MS (YPrime) and Jennifer Ross, MPhilEd (Almac) PDF version  
• April 1, 2015
  

  Defining the Needs for next Generation Assays for Tuberculosis

  Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M. Defining the Needs for next Generation Assays for Tuberculosis. The Journal of Infectious Diseases. 2015 Apr 1;211 Suppl 2:S29–38.

• April 1, 2015
  

  Integration of Published Information into a Resistance-Associated Mutation Database for Mycobacterium Tuberculosis

  Salamon H, Yamaguchi KD, Cirillo DM, Miotto P, Schito M, Posey J, Starks AM, Niemann S, Alland D, Hanna D, Aviles E, Perkins MD, Dolinger DL. Integration of Published Information into a Resistance-Associated Mutation Database for Mycobacterium Tuberculosis. The Journal of Infectious Diseases. 2015 Apr 1;211 Suppl 2:S50–7.

• April 1, 2015
  

  Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects

  Pai M, Schito M. Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects. The Journal of Infectious Diseases. 2015 Apr 1;211 Suppl 2:S21–8.